{
  "functional_evidence_assessment": {
    "variant_id": {
      "Gene": "PARK2",
      "Protein_Change": {
        "ref": "L858R",
        "alt": "",
        "position": "858"
      },
      "variant_string_id": "PARK2 L858R"
    },
    "functional_evidence_aim": "Pathogenic",
    "assessment_steps": [
      {
        "step_name": "Step 1: Define the disease mechanism",
        "extracted_paper_info": "Autosomal recessive juvenile parkinsonism (AR-JP) is characterized by selective dopaminergic neural cell death and the absence of the Lewy body.",
        "judgment": "Yes",
        "reasoning": "The paper clearly defines the disease mechanism as selective dopaminergic neuronal cell death without Lewy bodies, which is directly relevant to the function of the PARK2 parkin protein."
      },
      {
        "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
        "extracted_paper_info": "The ubiquitin-protein ligase activity of parkin was tested using standard proteasome assays.",
        "judgment": "Yes",
        "reasoning": "The general class of assay (ubiquitin-protein ligase activity) is applicable to the disease mechanism described in Step 1."
      },
      {
        "step_name": "Step 3: Evaluate validity of specific instances of assays",
        "extracted_paper_info": "The paper includes multiple replicates and does not mention any issues with controls.",
        "judgment": "Yes",
        "next_step_or_outcome": "Proceed to Step 4"
      },
      {
        "step_name": "Step 3c: Variant Controls",
        "extracted_paper_info": "Variant controls were used in the assay for this variant, specifically known pathogenic variants.",
        "judgment": "Yes",
        "next_step_or_outcome": null
      }
    ],
    "final_evidence_strength": {
      "type": "Pathogenic",
      "strength": "PS3_supporting"
    },
    "overall_conclusion": "The variant Parkin L858R is classified as pathogenic with supporting evidence based on the demonstrated role of parkin in protein degradation and its loss of ubiquitin-ligase activity in AR-JP patients."
  }
}